Loading...
•
Jun 30, 2020
Myriad Genetics Q4 2020 Earnings Report
Myriad Genetics experienced a significant recovery in test volume trends throughout the quarter, with volumes in late June increasing to approximately 75% of the pre-pandemic level.
Key Takeaways
Myriad Genetics, Inc. reported financial results for the fiscal fourth-quarter 2020. The company saw a significant recovery in test volume trends throughout the quarter. Total fourth-quarter revenues were $93.2 million and Fourth-Quarter Diluted EPS was ($0.74) and Adjusted EPS of ($0.31).
Test Volumes Improved Meaningfully By the End of the Fourth Quarter Following Substantial Declines in March and April Due to the Initiation of Social Distancing Policies
Total Fourth-Quarter Revenues of $93.2 Million
Fourth-Quarter Diluted EPS of ($0.74) and Adjusted EPS of ($0.31)
Total cash and cash equivalents and marketable securities increased sequentially in the fiscal fourth quarter to $254.8 million.
Revenue by Segment
Forward Guidance
Given the continued unpredictability pertaining to the COVID-19 pandemic and the impact it has had on both customer behavior and our ability to market our tests to physician customers, the company continues to see a wide range of possible financial outcomes for fiscal year 2021. As a result, the company has decided to not provide fiscal year 2021 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...